2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le vendredi 12 juillet 2013
Doi : 10.1016/j.jaad.2013.05.028
accepted : 30 May 2013
Treatment of pyoderma gangrenosum with mycophenolate mofetil as a steroid-sparing agent

Jane Li, MBBS, BMedSci , Robert Kelly, MBBS, FACD
 Department of Dermatology, St Vincent's Hospital Melbourne, Victoria, Australia 

Reprint requests: Jane Li, MBBS, BMedSci, Department of Dermatology, St Vincent's Hospital Melbourne, 41 Victoria Parade, Fitzroy, Victoria, Australia 3065.

Mycophenolate mofetil (MMF) has enjoyed increasing popularity as an emerging immunosuppressant treatment for various autoimmune dermatologic conditions, including pyoderma gangrenosum (PG).


The aim of this study was to examine the efficacy and safety of MMF as used in PG.


A retrospective chart review was conducted for all patients with PG treated with MMF at our institution (Victoria, Australia) for the past 11 years (2001-2012).


We identified 26 patients, 14 female and 12 male. Nine patients (34.6%) had associated systemic conditions. All patients received prednisolone. MMF was used as a first-line steroid-sparing agent in 11 patients (42.3%), second-line in 14 (53.8%), and third-line in 1 (3.85%). The average duration of treatment was 12.1 months. Fourteen patients experienced side effects (53.8%), although most were mild (26.9%). One patient died after a sigmoid colon perforation (3.85%). Overall 22 patients demonstrated clinical improvement during MMF treatment (84.6%). Thirteen patients achieved complete ulcer healing (50%), 10 while taking MMF and 3 after ceasing it.


This is a retrospective study based on a single-center cohort.


Our experience suggests that MMF is highly efficacious in PG together with prednisolone, or as part of combination therapy with other immunosuppressants.

The full text of this article is available in PDF format.

Key words : autoimmune disease, immunosuppression, mycophenolate mofetil, mycophenolate sodium, pyoderma gangrenosum, steroid-sparing agent, ulcers

 Funding sources: None.
 Conflicts of interest: None declared.

© 2013  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline